Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

Respiratory Research

Barbara A McQuade³  Kevin Smart⁴  Claire L Ambery³  Shu-Yen Ho²  Neil G Snowise¹  Richard MA Follows³ 

[1] Current address: Vectura Group plc, One Prospect West, Chippenham, Wiltshire SN14 6FH, UK;GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 2770, USA;GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK;Current address: Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, UK

关键词: Dose-ranging;    Tolerability;    Safety;    Efficacy;    Asthma;    FLAP;    GSK2190915;   

Others  :  794640
DOI  :  10.1186/1465-9921-14-54

 received in 2012-12-11, accepted in 2013-05-15,  发布年份 2013

【 摘 要 】

Background

GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma. The objective of this study was to evaluate GSK2190915 efficacy, dose–response and safety in subjects with persistent asthma treated with short-acting beta2-agonists (SABAs) only.

Methods

Eight-week multicentre, randomised, double-blind, double-dummy, stratified (by age and smoking status), parallel-group, placebo-controlled study in subjects aged ≥12 years with a forced expiratory volume in 1 second (FEV₁) of 50–85% predicted. Subjects (n = 700) were randomised to receive once-daily (QD) oral GSK2190915 (10–300 mg), twice-daily inhaled fluticasone propionate 100 μg, oral montelukast 10 mg QD or placebo. The primary endpoint was mean change from baseline (randomisation) in trough (morning pre-dose and pre-rescue bronchodilator) FEV₁ at the end of the 8-week treatment period. Secondary endpoints included morning and evening peak expiratory flow, symptom-free days and nights, rescue-free days and nights, day and night-time symptom scores, day and night-time rescue medication use, withdrawals due to lack of efficacy, Asthma Control Questionnaire and Asthma Quality of Life Questionnaire scores.

Results

For the primary endpoint, there was no statistically significant difference between any dose of GSK2190915 QD and placebo. However, repeated measures sensitivity analysis demonstrated nominal statistical significance for GSK2190915 30 mg QD compared with placebo (mean difference: 0.115 L [95% confidence interval: 0.00, 0.23], p = 0.044); no nominally statistically significant differences were observed with any of the other doses. For the secondary endpoints, decreases were observed in day-time symptom scores and day-time SABA use for GSK2190915 30 mg QD versus placebo (p ≤ 0.05). No dose–response relationship was observed for the primary and secondary endpoints across the GSK2190915 dose range studied; the 10 mg dose appeared to be sub-optimal. GSK2190915 was associated with a dose-dependent reduction in urinary leukotriene E₄. The profile and incidence of adverse events were similar between treatment groups.

Conclusion

Efficacy was demonstrated for GSK2190915 30 mg compared with placebo in day-time symptom scores and day-time SABA use. No additional improvement on efficacy endpoints was gained by administration of GSK2190915 doses greater than 30 mg. GSK2190915 was well-tolerated. These results may support further studies with GSK2190915 30 mg.

Trial registration

Clinicaltrials.gov:NCT01147744.

【 授权许可】

   
2013 Follows et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
• [2]Miyahara N, Miyahara S, Takeda K, Gelfand EW: Role of the LTB4/BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation. Allergol Int 2006, 55:91-97.
• [3]Hicks A, Monkarsh SP, Hoffman AF, Goodnow R Jr: Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007, 16:1909-1920.
• [4]Barnes NC, Piper PJ, Costell JF: Comparative effects of inhaled leukotriene C4, leukotriene D4 and histamine in normal subjects. Thorax 1984, 39:500-504.
• [5]Lewis RA: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990, 323:645-655.
• [6]Wenzel SE: The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 2003, 69:145-155.
• [7]Peters-Golden M, Henderson WR: Leukotrienes. N Engl J Med 2007, 357:1841-1854.
• [8]Dworski R, Fitzgerald GA, Oates JA, Sheller JR: Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994, 149:953-959.
• [9]Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997, 156:737-743.
• [10]Vachier I, Bonnans C, Chavis C, Farce M, Godard P, Bousquet J, Chanez P: Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005, 115:55-60.
• [11]Afonso PV, Janka-Junttila M, Lee YJ, McCann CP, Oliver CM, Aamer KA, Losert W, Cicerone MT, Parent CA: LTB4 is a signal-relay molecule during neutrophil chemotaxis. Dev Cell 2012, 22:1079-1091.
• [12]Vachier I, Kumlin M, Dahlen SE, Bousquet J, Godard P, Chanez P: High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respir Med 2003, 97:1225-1229.
• [13]Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ: Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999, 160:1532-1539.
• [14]From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2011. http://www.ginasthma.org/ webcite
• [15]Amlani S, Nadarajah T, McIvor RA: Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother 2011, 12:2119-2128.
• [16]Berger W, De Chandt MT, Cairns CB: Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007, 61:663-676.
• [17]Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich PP, Darlington JV, Stock NS, Zunic J, King CD, Lee C, Baccei CS, Stearns B, Roppe J, Hutchinson JH, Prasit P, Evans JF: Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur J Pharmacol 2010, 640:211-218.
• [18]Bain G, King C, Schaab K, Rewolinsk M, Norris V, Ambery C, Bentley J, Yamada M, Santini AM, van de Wetering de Rooij J, Stock N, Zunic J, Huitchinson JH, Evans JH: Pharmacodynamics, pharmacokinetics, and safety of GSK2190915, a potent, novel 5-lipoxygenase-activating protein inhibitor. Br J Clin Pharmacol 2013, 75:779-790.
• [19]National Institutes of Health (NIH): Guidelines for the Diagnosis and Management of Asthma - Expert Panel Report 3. NIH Publication No. 07–4051. Bethesda, MD: U.S. Department of Health and Human Services; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/ webcite
• [20]García-Marcos L, Schuster A, Pérez-Yarza EG: Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf 2003, 26:483-518.
• [21]Wasfi YS, Villarán C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF, Knorr BA: The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma. Respir Med 2012, 106:34-46.
• [22]Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM: The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993, 119:1059-1066.
• [23]Price D, Chisholm A, van der Molen T, Roche N, Hillyer EV, Bousquet J: Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep 2011, 11:526-538.